High-Profile CAR-T Therapies and DS-8201 Excluded from China's 2023 National Reimbursement Drug List Despite Passing Initial Review

Reporters found that two highly anticipated million-dollar CAR-T cell therapies, namely Fosun Kite's Axicabtagene Ciloleucel Injection and JW Therapeutics' Relmacabtagene Autoleucel Injection, as well as AstraZeneca's "miracle breast cancer drug" Trastuzumab Deruxtecan Injection (DS8201), did not appear in the list of the 2023 National Medical Insurance Catalog released today. All three drugs had previously passed the formal review. (Cailian Press)Original Link